http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2025, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 07 May 2025 15:56:55 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Investing/Charles+River+to+initiate+a+review+amid+Elliott+stake+-+Is+a+sale+next%3F/24757251.html <p dir="ltr">Investing.com -- Charles River Laboratories (NYSE:CRL) announced Wednesday it will appoint four new directors to its board and launch a comprehensive strategic review following a cooperation agreement with activist hedge fund Elliott Investment Management, the company’s largest shareholder. The changes will be overseen by a newly formed Strategic Planning and Capital Allocation Committee aimed at enhancing long-term shareholder value.</p><p dir="ltr">The move comes amid increased pressure on Charles River following a steep decline in its stock price and an FDA announcement of the “phasing-out” of animal testing requirements in preclinical research. Sources familiar with the agreement told Investing.com that Elliott http://www.streetinsider.com/Investing/Charles+River+to+initiate+a+review+amid+Elliott+stake+-+Is+a+sale+next%3F/24757251.html Wed, 07 May 2025 15:56:55 -0400 CAH CRL CTLT SYNH TMO http://www.streetinsider.com/Investing/Charles+River+to+initiate+a+review+amid+Elliott+stake+-+Is+a+sale+next%3F/24757251.html <p dir="ltr">Investing.com -- Charles River Laboratories (NYSE:CRL) announced Wednesday it will appoint four new directors to its board and launch a comprehensive strategic review following a cooperation agreement with activist hedge fund Elliott Investment Management, the company’s largest shareholder. The changes will be overseen by a newly formed Strategic Planning and Capital Allocation Committee aimed at enhancing long-term shareholder value.</p><p dir="ltr">The move comes amid increased pressure on Charles River following a steep decline in its stock price and an FDA announcement of the “phasing-out” of animal testing requirements in preclinical research. Sources familiar with the agreement told Investing.com that Elliott http://www.streetinsider.com/Investing/Charles+River+to+initiate+a+review+amid+Elliott+stake+-+Is+a+sale+next%3F/24757251.html Wed, 07 May 2025 15:56:55 -0400 CAH CRL CTLT SYNH TMO http://www.streetinsider.com/Investing/Charles+River+to+initiate+a+review+amid+Elliott+stake+-+Is+a+sale+next%3F/24757251.html <p dir="ltr">Investing.com -- Charles River Laboratories (NYSE:CRL) announced Wednesday it will appoint four new directors to its board and launch a comprehensive strategic review following a cooperation agreement with activist hedge fund Elliott Investment Management, the company’s largest shareholder. The changes will be overseen by a newly formed Strategic Planning and Capital Allocation Committee aimed at enhancing long-term shareholder value.</p><p dir="ltr">The move comes amid increased pressure on Charles River following a steep decline in its stock price and an FDA announcement of the “phasing-out” of animal testing requirements in preclinical research. Sources familiar with the agreement told Investing.com that Elliott http://www.streetinsider.com/Investing/Charles+River+to+initiate+a+review+amid+Elliott+stake+-+Is+a+sale+next%3F/24757251.html Wed, 07 May 2025 15:56:55 -0400 CAH CRL CTLT SYNH TMO http://www.streetinsider.com/Investing/Charles+River+to+initiate+a+review+amid+Elliott+stake+-+Is+a+sale+next%3F/24757251.html <p dir="ltr">Investing.com -- Charles River Laboratories (NYSE:CRL) announced Wednesday it will appoint four new directors to its board and launch a comprehensive strategic review following a cooperation agreement with activist hedge fund Elliott Investment Management, the company’s largest shareholder. The changes will be overseen by a newly formed Strategic Planning and Capital Allocation Committee aimed at enhancing long-term shareholder value.</p><p dir="ltr">The move comes amid increased pressure on Charles River following a steep decline in its stock price and an FDA announcement of the “phasing-out” of animal testing requirements in preclinical research. Sources familiar with the agreement told Investing.com that Elliott http://www.streetinsider.com/Investing/Charles+River+to+initiate+a+review+amid+Elliott+stake+-+Is+a+sale+next%3F/24757251.html Wed, 07 May 2025 15:56:55 -0400 CAH CRL CTLT SYNH TMO http://www.streetinsider.com/Investing/Charles+River+to+initiate+a+review+amid+Elliott+stake+-+Is+a+sale+next%3F/24757251.html <p dir="ltr">Investing.com -- Charles River Laboratories (NYSE:CRL) announced Wednesday it will appoint four new directors to its board and launch a comprehensive strategic review following a cooperation agreement with activist hedge fund Elliott Investment Management, the company’s largest shareholder. The changes will be overseen by a newly formed Strategic Planning and Capital Allocation Committee aimed at enhancing long-term shareholder value.</p><p dir="ltr">The move comes amid increased pressure on Charles River following a steep decline in its stock price and an FDA announcement of the “phasing-out” of animal testing requirements in preclinical research. Sources familiar with the agreement told Investing.com that Elliott http://www.streetinsider.com/Investing/Charles+River+to+initiate+a+review+amid+Elliott+stake+-+Is+a+sale+next%3F/24757251.html Wed, 07 May 2025 15:56:55 -0400 CAH CRL CTLT SYNH TMO